Mitchell Stephen Ray's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed Nov 18, 2024
- Accession no.
- 0000950170-24-128115
- Filed
- Nov 18, 2024
- Trade date
- Nov 14, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $25.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mitchell Stephen RayCIK 0001802653 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Common Stock | SSaleDisposed | −5,000 | $5.17 | −$25,850 | 44,857 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.